(CercleFinance.com) – The stock ended the session up more than 2%, benefiting from Berenberg’s positive analysis. The research office announced on Friday that it had raised bioMérieux from 114.5 to 122.2 euros, while renewing its purchase recommendation on the stock.
In a research note, the German financial intermediary believes that the recent correction suffered by the stock is unjustified, creating an interesting entry point into the value.
For the analyst, the diagnostic specialist displays solid prospects in the medium term, as the well-received investor day of April 9 demonstrated, and the management team was able to clearly explain the trajectory it intended borrow in order to achieve your goals.